Combination of HMG-CoA reductase rosuvastatin a phosphodiesterase 4 as roflumilast, roflumilast N-oxide for the treatment of inflammatory lung diseases

摘要

A pharmaceutical composition comprising a pharmaceutical formulation including an amount of a PDE4 inhibitor, an amount of a HMG-CoA reductase and at least one pharmaceutically acceptable adjuvant, wherein the PDE4 inhibitor is selected from the group is ROFLUMILAST a pharmaceutically acceptable salt of ROFLUMILAST, ROFLUMILAST-N-oxide and a pharmaceutically acceptable ROFLUMILAST-N-oxide salt, HMG-CoA reductase inhibitor is ROSUVASTATIN or a pharmaceutically acceptable salt thereof and wherein the first amount and the second amount together comprise an effective preventive or curative treatment of an inflammatory pulmonary disease amount.